Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Intercalated chemotherapy and icotinib versus chemotherapy followed by icotinib maintenance in EGFR-mutant advanced non-small cell lung cancer
ChiCTR-TRC-14004885Phase 4Recruiting
- Sponsor
- The First Affiliated Hospital of Guangxi Medical University
- Start
- Jul 2014
- Modality
- Small Molecules, Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 4, randomised, open-label trial of icotinib, gemcitabine and cisplatin in non-small cell lung cancer (NSCLC) (2 arms), sponsored by The First Affiliated Hospital of Guangxi Medical University. Primary endpoint: progression-free survival. Started Jul 2014; status: recruiting.
02
Drugs
icotinibgemcitabinecisplatin
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on ChiCTR-TRC-14004885.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR-TRC-14004885.